{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:28Z","timestamp":1787063068273,"version":"build-2736575974"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1097\/01.ftd.0000169061.52715.3e","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T04:01:51Z","timestamp":1127188911000},"page":"647-654","source":"Crossref","is-referenced-by-count":88,"title":["Thiopurine Therapies"],"prefix":"10.1097","volume":"27","author":[{"given":"John A","family":"Duley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy H. J","family":"Florin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210129","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjgastroenterol.2003.11.002","article-title":"Maintenance therapy for inflammatory bowel disease.","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R2-18-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/074823378600200201","article-title":"Historical background of 6-mercaptopurine.","volume":"2","author":"Elion","year":"1986","journal-title":"Toxicol Ind Health"},{"key":"R3-18-20210129","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1749-6632.1954.tb40021.x","article-title":"The fate of 6-mercaptopurine in man.","volume":"60","author":"Hamilton","year":"1954","journal-title":"Ann N Y Acad Sci"},{"key":"R4-18-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.2042-7158.1983.tb04255.x","article-title":"Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine in human red blood cells.","volume":"35","author":"Lennard","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"R5-18-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.1986.178","article-title":"Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.","volume":"40","author":"Lennard","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"R6-18-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-4347(92)80347-S","article-title":"High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thio-inosinic acid and 6-methylmercaptopurine metabolites in a single sample.","volume":"583","author":"Lennard","year":"1992","journal-title":"J Chromatogr"},{"key":"R7-18-20210129","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/0006-2952(74)90044-6","article-title":"Formation of 5-nucleotides of 6-methylmercaptopurine ribonucleoside in human tissues in vitro.","volume":"23","author":"Zimmerman","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"R8-18-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.","volume":"336","author":"Lennard","year":"1990","journal-title":"Lancet"},{"key":"R9-18-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0009-8981(78)90311-X","article-title":"Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.","volume":"85","author":"Weinshilboum","year":"1978","journal-title":"Clin Chim Acta"},{"key":"R10-18-20210129","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"key":"R11-18-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/clpt.1987.4","article-title":"Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.","volume":"41","author":"Lennard","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R12-18-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"R13-18-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00008571-199608000-00001","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.","volume":"6","author":"Krynetski","year":"1996","journal-title":"Pharmacogenetics"},{"key":"R14-18-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1073\/pnas.92.4.949","article-title":"A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.","volume":"92","author":"Krynetski","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-18-20210129","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood.V85.7.1897.bloodjournal8571897","article-title":"Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.","volume":"85","author":"McLeod","year":"1995","journal-title":"Blood"},{"key":"R16-18-20210129","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","article-title":"Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.","volume":"126","author":"Yates","year":"1997","journal-title":"Ann Intern Med"},{"key":"R17-18-20210129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0009-9236(98)90021-2","article-title":"Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and3C) and its association with loss of TPMT protein and catalytic activity in humans.","volume":"64","author":"Loennechen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"R18-18-20210129","first-page":"601","article-title":"Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.","volume":"29","author":"Weinshilboum","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R19-18-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007691-200404000-00024","article-title":"Analytic aspects of monitoring therapy with thiopurine medications.","volume":"26","author":"Armstrong","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R20-18-20210129","first-page":"RA247","article-title":"Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice.","volume":"10","author":"Cara","year":"2004","journal-title":"Med Sci Monit"},{"key":"R21-18-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/rheumatology\/keg442","article-title":"Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.","volume":"43","author":"Clunie","year":"2004","journal-title":"Rheumatol"},{"key":"R22-18-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00007691-200404000-00018","article-title":"Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.","volume":"26","author":"Evans","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R23-18-20210129","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11894-003-0041-7","article-title":"Optimizing immunomodulator therapy for inflammatory bowel disease.","volume":"5","author":"Dubinsky","year":"2003","journal-title":"Curr Gastroenterol Rep"},{"key":"R24-18-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-4347(95)00432-7","article-title":"Thiopurine methyltransferase: a review and a clinical pilot study.","volume":"678","author":"Keuzenkamp-Jansen","year":"1996","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R25-18-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000028394","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance.","volume":"61","author":"Krynetski","year":"2000","journal-title":"Pharmacology"},{"key":"R26-18-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00007691-199810000-00014","article-title":"Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions.","volume":"20","author":"Lennard","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R27-18-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14622416.3.1.89","article-title":"The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics.","volume":"3","author":"McLeod","year":"2002","journal-title":"Pharmacogenomics"},{"key":"R28-18-20210129","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/00054725-200402001-00008","article-title":"Pharmacogenomics and IBD: TPMT and thiopurines.","volume":"10","author":"Sandborn","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R29-18-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1258\/0004563041201455","article-title":"Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?","volume":"41","author":"Sanderson","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"R30-18-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-002-0442-6","article-title":"Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.","volume":"50","author":"Lancaster","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R31-18-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007691-199606000-00002","article-title":"Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?","volume":"18","author":"Schutz","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R32-18-20210129","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/adc.69.5.577","article-title":"Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.","volume":"69","author":"Lennard","year":"1993","journal-title":"Arch Dis Child"},{"key":"R33-18-20210129","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/00365520410007980","article-title":"Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.","volume":"39","author":"Hindorf","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"R34-18-20210129","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","article-title":"Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.","volume":"93","author":"Relling","year":"1999","journal-title":"Blood"},{"key":"R35-18-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R36-18-20210129","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.1989.7.12.1816","article-title":"Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.","volume":"7","author":"Lennard","year":"1989","journal-title":"J Clin Oncol"},{"key":"R37-18-20210129","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.49.5.665","article-title":"Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"key":"R38-18-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004836-200305000-00005","article-title":"Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.","volume":"36","author":"Mardini","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"R39-18-20210129","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/gut.2003.032896","article-title":"Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.","volume":"53","author":"Wright","year":"2004","journal-title":"Gut"},{"key":"R40-18-20210129","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2004.01947.x","article-title":"Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohns disease.","volume":"19","author":"Herrlinger","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-18-20210129","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/00365520310005082","article-title":"Pharmacological monitoring of azathioprine therapy.","volume":"38","author":"Reuther","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"R42-18-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00007691-200206000-00005","article-title":"Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.","volume":"24","author":"Pettersson","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R43-18-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/gut.51.2.143","article-title":"TPMT in the treatment of Crohns disease with azathioprine.","volume":"51","author":"Lennard","year":"2002","journal-title":"Gut"},{"key":"R44-18-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/978-1-4615-2584-4_122","article-title":"The muscle and nonmuscle isozymes of adenylosuccinate synthetase are encoded by separate genes with differential patterns of expression.","volume":"370","author":"Guicherit","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"R45-18-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0009-8981(95)06088-U","article-title":"Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method.","volume":"238","author":"Montero","year":"1995","journal-title":"Clin Chim Acta"},{"key":"R46-18-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0009-8981(88)90145-3","article-title":"Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism.","volume":"171","author":"Simmonds","year":"1988","journal-title":"Clin Chim Acta"},{"key":"R48-18-20210129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1172\/JCI113707","article-title":"Oxypurine cycle in human erythrocytes regulated by pH, inorganic phosphate, and oxygen.","volume":"82","author":"Berman","year":"1988","journal-title":"J Clin Invest"},{"key":"R49-18-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bjc.1993.311","article-title":"Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?","volume":"68","author":"Lennard","year":"1993","journal-title":"Br J Cancer"},{"key":"R50-18-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00684949","article-title":"Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice.","volume":"28","author":"Kurowski","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"R51-18-20210129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2141.1998.00812.x","article-title":"Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.","volume":"102","author":"Lancaster","year":"1998","journal-title":"Br J Haematol"},{"key":"R52-18-20210129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/004982599238434","article-title":"In vitro metabolism of 6-mercaptopurine by human liver cytosol.","volume":"29","author":"Rowland","year":"1999","journal-title":"Xenobiotica"},{"key":"R53-18-20210129","first-page":"S30","article-title":"Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.","volume":"3","author":"Seidman","year":"2003","journal-title":"Rev Gastroenterol Dis"},{"key":"R54-18-20210129","first-page":"680","article-title":"Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders.","volume":"6","author":"Seidman","year":"2004","journal-title":"US Patent"},{"key":"R55-18-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2125.1993.tb00365.x","article-title":"Red blood cell hypoxanthine phosphoribosyl-transferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia.","volume":"36","author":"Lennard","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"R56-18-20210129","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","article-title":"Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.","volume":"91","author":"Relling","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R57-18-20210129","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00007691-200412000-00014","article-title":"Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.","volume":"26","author":"Hindorf","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R58-18-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004836-200209000-00008","article-title":"Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohns disease.","volume":"35","author":"Regueiro","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R59-18-20210129","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.","volume":"19","author":"Evans","year":"2001","journal-title":"J Clin Oncol"},{"key":"R60-18-20210129","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","article-title":"Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.","volume":"16","author":"Ansari","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R61-18-20210129","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/1529-0131(199810)41:10<1858::AID-ART19>3.0.CO;2-8","article-title":"Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis.","volume":"41","author":"Stolk","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R62-18-20210129","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"R63-18-20210129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","article-title":"Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).","volume":"14","author":"Marinaki","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R64-18-20210129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1445-5994.2003.00321.x","article-title":"6-thioguanine: a new old drug to procure remission in inflammatory bowel disease.","volume":"33","author":"Cheung","year":"2003","journal-title":"Intern Med J"},{"key":"R65-18-20210129","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00007691-199608000-00003","article-title":"Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.","volume":"18","author":"Lennard","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R66-18-20210129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002800050816","article-title":"Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.","volume":"42","author":"Erb","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"R67-18-20210129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1373\/49.2.260","article-title":"Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods.","volume":"49","author":"Shipkova","year":"2003","journal-title":"Clin Chem"},{"key":"R68-18-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","article-title":"Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC.","volume":"44","author":"Dervieux","year":"1998","journal-title":"Clin Chem"},{"key":"R69-18-20210129","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1373\/49.9.1551","article-title":"Commentary on: Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods.","volume":"49","author":"Lennard","year":"2003","journal-title":"Clin Chem"},{"key":"R70-18-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-4347(95)00206-X","article-title":"Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid chromatography.","volume":"672","author":"Keuzenkamp-Jansen","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R72-18-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/clinchem\/48.1.61","article-title":"HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.","volume":"48","author":"Dervieux","year":"2002","journal-title":"Clin Chem"},{"key":"R73-18-20210129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00007691-199708000-00003","article-title":"Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.","volume":"19","author":"Welch","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R74-18-20210129","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-199205000-00016","article-title":"The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.","volume":"53","author":"Chocair","year":"1992","journal-title":"Transplantation"},{"key":"R75-18-20210129","first-page":"359","article-title":"Fast and slow methylators: do racial differences influence risk of allograft rejection?","volume":"86","author":"Chocair","year":"1993","journal-title":"Q J Med"},{"key":"R76-18-20210129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"R77-18-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.1996.tb00021.x","article-title":"Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.","volume":"42","author":"Lennard","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R78-18-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2125.1997.t01-1-00607.x","article-title":"Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.","volume":"44","author":"Lennard","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R79-18-20210129","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00007691-199712000-00010","article-title":"Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods.","volume":"19","author":"Giverhaug","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R80-18-20210129","first-page":"5810","article-title":"Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.","volume":"61","author":"Dervieux","year":"2001","journal-title":"Cancer Res"},{"key":"R81-18-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0925-4439(93)90110-M","article-title":"The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts.","volume":"1181","author":"Vogt","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"R82-18-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/978-1-4615-5381-6_133","article-title":"Thiopurine treatment in childhood leukemia. Metabolic aspects and sensitivity.","volume":"431","author":"De Abreu","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"R83-18-20210129","first-page":"1141","article-title":"Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.","volume":"47","author":"Krynetski","year":"1995","journal-title":"Mol Pharmacol"},{"key":"R84-18-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5858\/2004-128-49-ENHOTL","article-title":"Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy.","volume":"128","author":"Shrastri","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"R85-18-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2003.04578.x","article-title":"Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.","volume":"123","author":"Stoneham","year":"2003","journal-title":"Br J Haematol"},{"key":"R86-18-20210129","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","article-title":"6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients.","volume":"125","author":"Dubinsky","year":"2003","journal-title":"Gastroenterology"},{"key":"R87-18-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/00008571-200411000-00010","article-title":"Lack of association between the ITPA 94CA polymorphism and adverse effects from azathioprine.","volume":"14","author":"Gearry","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R88-18-20210129","first-page":"3686","article-title":"Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine.","volume":"54","author":"Yen","year":"1994","journal-title":"Cancer Res"},{"key":"R89-18-20210129","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5","article-title":"Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.","volume":"86","author":"Bo","year":"1999","journal-title":"Cancer"},{"key":"R90-18-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.leu.2400928","article-title":"Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia.","volume":"12","author":"Relling","year":"1998","journal-title":"Leukemia"},{"key":"R91-18-20210129","first-page":"1868","article-title":"Effects of 6-thioguanine on macromolecular events in regenerating rat liver.","volume":"37","author":"Carrico","year":"1977","journal-title":"Cancer Res"},{"key":"R92-18-20210129","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"R93-18-20210129","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0165-6147(99)01361-9","article-title":"Efficacy in drug receptor theory: outdated concept or under-valued tool?","volume":"20","author":"Kenakin","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"R94-18-20210129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.104.074815","article-title":"Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines.","volume":"312","author":"Thomas","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R95-18-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08923978109026415","article-title":"Differential inhibition by azathioprine and 6-mercaptopurine of specific suppressor T cell generation in mice.","volume":"3","author":"Medzihradsky","year":"1981","journal-title":"J Immunopharmacol"},{"key":"R96-18-20210129","first-page":"160","article-title":"6-Mercaptopurine levels and study of blood lymphocyte subsets during azathioprine treatment of Crohns disease.","volume":"22","author":"Cattan","year":"1998","journal-title":"Gastroenterol Clin Biol"},{"key":"R97-18-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70445-2","article-title":"Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohns disease. North American Azathioprine Study Group.","volume":"117","author":"Sandborn","year":"1999","journal-title":"Gastroenterology"},{"key":"R98-18-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0140-6736(93)91287-V","article-title":"Low-dose allopurinol plus azathioprine\/cyclosporin\/prednisolone, a novel immunosuppressive regimen.","volume":"342","author":"Chocair","year":"1993","journal-title":"Lancet"},{"key":"R99-18-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00007691-199904000-00015","article-title":"Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine.","volume":"21","author":"Chrzanowska","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R100-18-20210129","first-page":"S49","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications. Leukopenia.","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R101-18-20210129","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/jpet.104.069286","article-title":"Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine.","volume":"311","author":"Menor","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R102-18-20210129","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2003.11.024","article-title":"Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury.","volume":"40","author":"Tapner","year":"2004","journal-title":"J Hepatol"},{"key":"R103-18-20210129","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/S0021-9258(18)99622-5","article-title":"Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization.","volume":"242","author":"Krenitsky","year":"1967","journal-title":"J Biol Chem"},{"key":"R104-18-20210129","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","article-title":"Genotypic analysis of thiopurine S-methyltransferase in patients with Crohns disease and severe myelosuppression during azathioprine therapy.","volume":"118","author":"Colombel","year":"2000","journal-title":"Gastroenterology"},{"key":"R105-18-20210129","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1053\/gast.2002.32124","article-title":"Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity.","volume":"122","author":"McGovern","year":"2002","journal-title":"Gastroenterology"},{"key":"R107-18-20210129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/08035259850158001","article-title":"Pharmacokinetics, dose adjustments, and 6-mercaptopurine\/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.","volume":"87","author":"Andersen","year":"1998","journal-title":"Acta Paediatr"},{"key":"R108-18-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s002800050672","article-title":"Methotrexate increases red blood cell concentrations of 6-methylmercaptopurine ribonucleotide in rats in vivo.","volume":"40","author":"Giverhaug","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"R109-18-20210129","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0006-2952(97)00681-3","article-title":"Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukemic cells in vitro by methotrexate.","volume":"55","author":"Giverhaug","year":"1998","journal-title":"Biochem Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.ftd.0000169061.52715.3e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:01:44Z","timestamp":1785855704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200510000-00018"}},"subtitle":["Problems, Complexities, and Progress With Monitoring Thioguanine Nucleotides"],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000169061.52715.3e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}